Literature DB >> 11388671

A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis.

V Nelson1, G E Davis, S A Maxwell.   

Abstract

The p53 protein has recently been reported to be capable of mediating apoptosis through a pathway that is not dependent on its transactivation function. We report here that the PIASy member of the protein inhibitor of activated STAT family inhibited p53's transactivation function without compromising its ability to induce apoptosis of the H1299 nonsmall cell lung carcinoma cell line. The p53 protein bound to PIASy in yeast two-hybrid assays and coprecipitated in complexes with p53 in immunoprecipitates from mammalian cells. PIASy inhibited the DNA-binding activity of p53 in nuclear extracts and blocked the ability of p53 to induce expression of two of its target genes, Bax and p21Waf1/Cip1, in H1299 cells. The block in p53-mediated induction of Bax and p21 was determined to be at the level of transactivation, since PIASy inhibited p53's ability to transactivate a p21/luciferase reporter construct. PIASy did not effect the incidence of apoptosis in H1299 cells upregulated for p53. PIASy appears to regulate p53-mediated functions and may direct p53 into a transactivation-independent mode of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11388671     DOI: 10.1023/a:1011392811628

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  19 in total

1.  PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.

Authors:  S Sachdev; L Bruhn; H Sieber; A Pichler; F Melchior; R Grosschedl
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

2.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.

Authors:  Darja Schmidt; Stefan Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 3.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

4.  Endometrial receptivity defects and impaired implantation in diabetic NOD mice.

Authors:  Ahmad J H Albaghdadi; Frederick W K Kan
Journal:  Biol Reprod       Date:  2012-08-02       Impact factor: 4.285

5.  SUMOylation of p53 mediates interferon activities.

Authors:  Laura Marcos-Villar; José V Pérez-Girón; Jéssica M Vilas; Atenea Soto; Carlos F de la Cruz-Hererra; Valerie Lang; Manuel Collado; Anxo Vidal; Manuel S Rodríguez; César Muñoz-Fontela; Carmen Rivas
Journal:  Cell Cycle       Date:  2013-08-05       Impact factor: 4.534

Review 6.  Emerging roles of SUMO modification in arthritis.

Authors:  Dongyao Yan; Francesca J Davis; Andrew D Sharrocks; Hee-Jeong Im
Journal:  Gene       Date:  2010-07-11       Impact factor: 3.688

7.  A novel role for protein inhibitor of activated STAT (PIAS) proteins in modulating the activity of Zimp7, a novel PIAS-like protein, in androgen receptor-mediated transcription.

Authors:  Yue Peng; Jane Lee; Chunfang Zhu; Zijie Sun
Journal:  J Biol Chem       Date:  2010-02-16       Impact factor: 5.157

8.  PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger.

Authors:  Zhiyong Deng; Meimei Wan; Guangchao Sui
Journal:  Mol Cell Biol       Date:  2007-03-12       Impact factor: 4.272

9.  Partial p53-dependence of anisomycin-induced apoptosis in PC12 cells.

Authors:  R Schipp; J Varga; J Bátor; M Vecsernyés; Z Árvai; M Pap; József Szeberényi
Journal:  Mol Cell Biochem       Date:  2017-04-21       Impact factor: 3.396

10.  Chromatin remodeling: demethylating H3K4me3 of type I IFNs gene by Rbp2 through interacting with Piasy for transcriptional attenuation.

Authors:  Xiaoli Yu; Hui Chen; Chen Zuo; Xi Jin; Yibing Yin; Hong Wang; Mei Jin; Keiko Ozato; Songxiao Xu
Journal:  FASEB J       Date:  2018-01-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.